The open-label extension study of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Nippon Shinyaku
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 26 May 2016 New trial record